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Abstract
Background: Microglia are the primary immune cells of the brain whose phenotype largely depends on their
surrounding micro-environment. Microglia respond to a multitude of soluble molecules produced by a variety of
brain cells. Macrophage colony-stimulating factor (M-CSF) is a cytokine found in the brain whose receptor is
expressed by microglia. Previous studies suggest a critical role for M-CSF in brain development and normal
functioning as well as in several disease processes involving neuroinflammation.
Methods: Using biopsy tissue from patients with intractable temporal epilepsy and autopsy tissue, we cultured
primary adult human microglia to investigate their response to M-CSF. Mixed glial cultures were treated with
25 ng/ml M-CSF for 96 hours. Proliferation and phagocytosis assays, and high through-put immunocytochemistry,
microscopy and image analysis were performed to investigate microglial phenotype and function.
Results: We found that the phenotype of primary adult human microglia was markedly changed following exposure
to M-CSF. A greater number of microglia were present in the M-CSF- treated cultures as the percentage of proliferating
(BrdU and Ki67-positive) microglia was greatly increased. A number of changes in protein expression occurred
following M-CSF treatment, including increased transcription factors PU.1 and C/EBPβ, increased DAP12 adaptor
protein, increased M-CSF receptor (CSF-1R) and IGF-1 receptor, and reduced HLA-DP, DQ, DR antigen presentation
protein. Furthermore, a distinct morphological change was observed with elongation of microglial processes. These
changes in phenotype were accompanied by a functional increase in phagocytosis of Aβ1-42 peptide.
Conclusions: We show here that the cytokine M-CSF dramatically influences the phenotype of adult human microglia.
These results pave the way for future investigation of M-CSF-related targets for human therapeutic benefit.
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Background
Microglial cells are brain-resident immune cells that have
many protective roles but can also contribute to neuro-
logical disease processes. The functional phenotype of
microglia depends on the cell types and specific activat-
ing factors in their surroundings, and for this reason
microglia are said to have an adaptive or acquired pheno-
type, reflecting their response to a collection of external
signals [1]. Secreted small molecules, such as cytokines
and growth factors, allow microglia to communicate with
each other, and with other immune and brain cells which
express these receptors [2]. In this way microglia can be
recruited to sites of injury, where they can respond by
ameliorating the damage [3,4]. However, there have also
been numerous reports of detrimental microglial activity
in response to injury, and neuroinflammation is thought
to play a major role in pathogenesis of many neurological
disorders, including epilepsy and Alzheimer’s disease [5-9].
The activation of microglia to a beneficial or detrimental
phenotype can be described in terms of inducible protein
expression, morphology, and functional outcomes such as
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cytokine production and phagocytosis [8,10]. Modulating
microglial phenotype towards a protective role is a poten-
tial strategy for the treatment of many brain disorders and
thus the factors influencing microglial activation require
further research.
One molecule that can influence microglial phenotype
is the cytokine macrophage colony-stimulating factor
(M-CSF). M-CSF is found in the brain and its receptor
is expressed by microglia [11,12]. M-CSF is produced by
a range of cells in the developing and adult brain [12,13].
M-CSF mRNA and protein have been found to be consti-
tutively expressed by human fetal astrocytes and low levels
of M-CSF mRNA and protein were detected in unstimu-
lated microglia cultures [14]. Du Yan et al. (1997) have
also demonstrated M-CSF expression in neurons of the
adult human brain [12].
Signaling through the M-CSF receptor (CSF-1R) is re-
quired for the development and differentiation of micro-
glia [15] and M-CSF has been shown to increase division
of rodent and human fetal microglia [14,16,17]. M-CSF
also has the ability to change microglial morphology
[18,19] and influence microglial activation [20,21]. M-CSF
signaling has been shown to be dependent on the tran-
scription factor PU.1 [22], a vital myeloid transcription
factor expressed by microglia in the adult human brain
[23]. Celada et al. (1996) found that sense PU.1 expression
constructs increased M-CSF-dependent proliferation in
mouse bone-marrow macrophages, and antisense PU.1
constructs reduced proliferation in response to M-CSF
[24]. They also found that sense PU.1 constructs gave
rise to increased M-CSF receptor expression, and it has
previously been demonstrated that PU.1 binds to the
c-fms promoter [25].
While M-CSF is important for normal brain develop-
ment and function [26], several studies have found abnor-
mal levels of M-CSF associated with neurological diseases.
M-CSF was demonstrated to be upregulated in brain tu-
mors [27,28] and a correlation was found between levels
of M-CSF and HIV-associated cognitive impairment [29].
Furthermore, within three months of HIV therapy, levels
of both M-CSF and viral RNA in the CSF were reduced
[29]. Despite Boissonneault et al. (2009) reporting benefi-
cial effects of M-CSF on cognitive impairment and Aβ1-42
deposition in a mouse model of Alzheimer’s disease, it
has been suggested that increased M-CSF expression could
contribute to Alzheimer’s disease pathogenesis [12,30].
Lue et al. (2001) cultured glia from adult human brains
and found that M-CSF was elevated in Alzheimer’s dis-
ease compared to non-demented microglia [31]. M-CSF
receptor expression in microglia in human brain tissue
was upregulated in lesions of Alzheimer’s disease and
amyotrophic lateral sclerosis [11]. On the contrary, while
microglia are found to be associated with multiple scler-
osis lesions, the relative number of microglia expressing
M-CSF and its receptor have been found to decrease [32].
M-CSF is therefore considered a key factor in regulating
microglial inflammatory responses in the damaged brain.
Despite this comprehensive body of literature, there
are several caveats which may prohibit the linking of
functional studies to observations in human brain tissue.
Although most of the research on M-CSF and microglia
has been carried out using rodent cells and models, it is
becoming increasingly clear that there are important
differences between rodent microglia and their human
counterpart [33,34]. Age has also been shown to have an
impact on immune cell responses and activation [35-37].
Furthermore, the micro-environment of the brain may
affect immune responses in ways that are different to
those of the periphery [4] and while the majority of re-
search on M-CSF has been carried out on peripheral
immune cells, the effects of M-CSF on adult human
microglia have not been fully investigated. We have thus
assessed the phenotypic profile of adult human microglia
after exposure to M-CSF and found that this cytokine dra-
matically influences their phenotype and activation state.
Methods
Tissue
Autopsy human adult brain tissue was obtained from the
Neurological Foundation of New Zealand Human Brain
Bank under the University of Auckland Human Subjects
Ethics Committee. Biopsy adult human brain tissue was
obtained from patients undergoing surgery for intractable
temporal lobe epilepsy and was approved by the Northern
Regional Ethics Committee with informed consent from
all tissue donors. The specimens used in this paper were
from confirmed temporal lobe epilepsy cases with varying
degrees of mild and moderate to marked mesial temporal
sclerosis (neuropathological grade 3 to 4). Patients had
taken a range of medications alone or in combination, in-
cluding phenytoin, tegretol, topiramate, lamotrigine, and
sodium valproate. There were no obvious associations
between the results of any of the reported experiments
and medication use or degree of sclerosis.
Human glial cell isolation and culture
Glial cells were isolated from adult human brain tissue as
previously described [38,39]. Approximately 2 g of middle
temporal gyrus white and grey matter was washed twice
in Hanks balanced salt solution (HBSS; Ca2+ and Mg2+
free, Gibco BRL, Carlsbad, CA, USA). The meninges
and visible blood vessels were removed. The tissue was
then diced into small (approximately 1 mm3) cubes and
placed in 10 ml/g tissue warm enzyme dissociation mix
containing 2.5 U/ml papain (Worthington, Lakewood, NJ,
USA) and 10 U/ml DNase (Invitrogen, Carlsbad, CA,
USA) in HBSS and incubated for 30 minutes at 37°C with
agitation. An equal volume of DMEM/F12 supplemented
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with 10% FBS, 1% penicillin-streptomycin-glutamine
(Gibco BRL, Carlsbad, CA, USA) (final concentrations:
penicillin (100 U/ml), streptomycin (100 μg/ml) and
L-glutamine (0.29 mg/ml)) was added to the tissue which
was then gently triturated. The cell suspension was passed
through a 100 μm nylon cell strainer (Becton Dickinson,
Franklin Lakes, NJ, USA), centrifuged for 10 minutes
at 160 g, the pellet resuspended in 20 ml medium and
plated into 75 cm2 tissue culture flasks (Nunc, Roskilde,
Denmark) which were incubated at 37°C in 95% air/5%
CO2. After 24 hours, the debris and unattached cells were
removed, centrifuged for 10 minutes at 160 g and replated
onto the adhered cells for a further 24 hours. Finally, the
debris was removed and the cells carefully washed with
medium. Cells were cultured for one to two weeks (in the
same medium as for isolation) prior to plating for experi-
ments at 50,000 cells/ml on 96-well plates.
M-CSF treatment
Mixed primary human glial cell cultures were given two
concentrations of 25 ng/ml M-CSF at 0 and 48 hours.
Total time of M-CSF treatment was 96 hours.
BrdU proliferation assay
Following 72 hours exposure to 25 ng/ml M-CSF, 10 μM
BrdU was added to the cells for 24 hours. Cells were
washed twice with PBS to remove excess BrdU and fixed
with 4% paraformaldehyde (PFA) for 15 minutes at room
temperature (RT). For immunocytochemistry, cells were
first incubated with 2 M HCl at 37°C for 30 minutes.
Cells were then washed twice in 0.1 M borate buffer
(pH 8.5) and three times in PBS before applying anti-
BrdU antibody.
Immunocytochemistry
Cells were fixed in 4% PFA for 15 minutes at RT then
washed for 10 minutes with phosphate-buffered saline
containing 0.2% Triton X-100 (PBS-T). Antibodies were
diluted in immuno-buffer (PBS-T containing 1% goat serum
and 0.04% merthiolate). Cells were incubated with primary
antibody (see Table 1) overnight at 4°C with gentle rocking.
Alexa Fluor-conjugated and biotinylated secondary
antibodies (Table 1) were applied for three hours at RT
with gentle rocking. For colorimetric protein detection,
ExtrAvidin-HRP was applied for two hours at RT followed
by 3,3′-diaminobenzidine tetrahydrochloride (DAB) reac-
tion. To label all nuclei, cells were stained with Hoechst
33258 (Sigma-Aldrich, St Louis, MO, USA) for 30 minutes
at RT protected from light. Cells were washed in TNE
buffer (pH 7.4) containing 10 mM Tris, 200 mM NaCl
and 1 mM EDTA prior to, and following, incubation in
20 μM Hoechst 33258 diluted in TNE buffer.
Phagocytosis assays
To evaluate the effect of M-CSF on primary adult human
microglial phagocytosis of amyloid-β1–42 amino acid pep-
tide (Aβ1-42; Bachem, Bubendorf, Switzerland), phagocytosis
assays were performed as previously described [39,40]. Fol-
lowing 72 hours exposure to 25 ng/ml M-CSF, 5 μM Aβ1-42
was added to the cells for 24 hours. Cells were washed
Table 1 Antibodies used for immunocytochemistry
Antibody Company Catalogue # Dilution
Rabbit anti-PU.1 Cell Signaling 2258 1:500
Mouse anti-CD45 Abcam ab8216 1:500
Rabbit anti-CSF-1R Santa Cruz Sc-692 1:50
Mouse anti-HLA-DP, DQ, DR Dako M0775 1:500
Mouse anti-GFAP Sigma-Aldrich G3893 1:5000
Mouse anti-Prolyl 4-hydroxylase Dako M0877 1:1000
Rabbit anti-DAP12 Santa Cruz Sc-20783 1:500
Mouse anti-C/EBPβ Santa Cruz Sc-7962 1:250
Mouse anti-IGF-1R Millipore MAB1120 1:50
Mouse anti-BrdU Roche 11170376001 1:500
Rabbit anti-Ki67 Dako A0047 1:500
Goat anti-rabbit IgG Alexa Fluor® 594 Invitrogen A11012 1:500
Goat anti-mouse IgG Alexa Fluor® 488 Invitrogen A11001 1:500
Goat anti-mouse IgG Alexa Fluor® 594 Invitrogen A11005 1:500
Goat anti-rabbit IgG Alexa Fluor® 488 Invitrogen A11008 1:500
Goat anti-rabbit biotinylated Sigma-Aldrich B7389 1:500
Goat anti-mouse biotinylated Sigma-Aldrich B7264 1:500
ExtrAvidin-HRP Sigma-Aldrich E2886 1:500
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twice with PBS to remove excess Aβ1-42 and fixed with
4% PFA for 15 minutes at RT. Thioflavin S was used to
visualize phagocytosed Aβ1-42 [40].
Quantitative image analysis of cell number, microglial
morphology and phagocytosis
Immunocytochemical, phagocytic and morphological
observations have been quantified using a Discovery-1
automated fluorescence microscope (Molecular Devices,
Sunnyvale, CA, USA) and Metamorph (6.2.6 software,
Molecular Devices, Sunnyvale, CA, USA) image analysis
system as previously described [40,41]. Results were
logged automatically to Microsoft Excel spreadsheets.
For quantification of microglial morphology, the Journal
‘Microglial Shape’ was written in Metamorph. The journal
automatically thresholded each image to isolate CD45-
positive microglia, then applied the Integrated Morphom-
etry Analysis tools Elliptical Form Factor (length/breadth)
and Shape Factor (4πA/P2, P = cell perimeter, A = cell
area) to determine cell shape.
Statistical Analysis
Representative data are displayed as mean ± standard
error of the mean (SEM). Experiments were replicated
with cells from at least six different individuals. Number
of replicates (n) for each experiment is indicated in
figure legends. Statistical analysis was carried out using
t-tests and P values of < 0.05 were considered statisti-
cally significant differences.
Results
Adult human microglia express the M-CSF receptor
in vitro
Primary mixed glial cultures containing microglia were
prepared from biopsy and autopsy adult human brain
tissue as previously described [38,39].
Figure 1 The macrophage colony-stimulating factor (M-CSF) receptor (CSF-1R) is expressed by adult human microglia in vitro. (A) Adult
human microglia in culture labeled for CD45 cell surface protein (green). (B) Same field of view showing microglial expression of PU.1 transcription
factor (red). (C) Brightfield image showing 3,3′-diaminobenzidine tetrahydrochloride (DAB)-labeling of CSF-1R in the same field of view. (D) Overlay of
images A, B and C demonstrating co-localization of CSF-1R with microglial markers CD45 and PU.1. (E) CSF-1R (brown) is not co-expressed by glial
fibrillary acid protein (GFAP)-positive astrocytes (green) in mixed glial cultures (all nuclei labeled with Hoechst, blue). (F) CSF-1R (brown) is not
expressed by prolyl-4-hydroxylase-positive fibroblast-like leptomeningeal cells (green) in mixed glial cultures (all nuclei labeled with Hoechst, blue).
Scale bar = 50 μm.
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In mixed cultures of adult human glial cells, the M-CSF
receptor (CSF-1R) was expressed by microglia. We found
that protein expression of CSF-1R coincided with microglial
cell surface protein CD45 (leukocyte common antigen)
and microglial transcription factor PU.1 (Figure 1A-D).
No CSF-1R expression was found on glial fibrillary acidic
protein (GFAP)-positive astrocytes or collagen synthe-
sizing enzyme prolyl-4-hydroxylase-positive fibroblast-
like leptomeningeal cells in the mixed glial cultures
(Figure 1E and F respectively).
M-CSF increases expression of microglial transcription
factor PU.1
To assess the response of adult human microglia to M-CSF,
we treated the mixed glial cultures with 25 ng/ml M-CSF
for 96 hours. We used the microglial transcription factor
PU.1 and the pan microglial cell surface protein CD45
to identify and count the number of microglia (Figure 2A,
B and 2C, D respectively). We observed and quantified
significantly more microglia in the cultures treated with
M-CSF than vehicle-treated cultures (Figure 2E).
The number of PU.1-positive and CD45-positive cells was
increased by M-CSF, reflecting the increase in microglial
number. However, we also found a significant increase in
PU.1 protein expression in microglia treated with M-CSF
(Figure 2F). Thus, M-CSF increases the amount of PU.1
within microglia as well as PU.1-positive microglial number.
M-CSF increases proliferation of adult human microglia
To further investigate the finding that more PU.1-positive
cells are present in cultures treated with M-CSF, we
assessed microglial proliferation. Adult human microglia
Figure 2 Macrophage colony-stimulating factor (M-CSF) treatment increases the number of microglia and expression of PU.1 in primary
adult human mixed glial cultures. (A) PU.1-positive microglia (red nuclei) are present in glial cultures from human brain tissue. (B) There are more
PU.1-positive cells with M-CSF treatment compared to vehicle treatment. The increase in microglia number is also seen by immunostaining for
microglial surface receptor CD45 (C and D). (E) Treatment of human glial cultures with 25 ng/ml M-CSF for 96 hours significantly increases the number
of microglia present. P < 0.0001, n = 6. (F) M-CSF significantly increases the intensity of PU.1 expression (amount of PU.1 protein) in adult human
microglia. P < 0.05, n = 6. Scale bar = 100 μm.
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basally proliferate at a very low rate (% dividing microglia as
measured by BrdU incorporation = 4.2 +/− 1.2% (mean +/−
SEM; n = 6 cases)). However, treatment with M-CSF mark-
edly increased microglial division (% dividing microglia
after M-CSF treatment = 12.6 +/− 2.0% (mean +/− SEM;
n = 6 cases)). M-CSF treatment resulted in a greater num-
ber of microglia expressing the cell division protein Ki67
(Figure 3A and B) and significantly increased BrdU in-
corporation by microglia (Figure 3C).
M-CSF increases adult human microglial phagocytosis
Phagocytosis is a key innate function of microglia. Their
ability to perform efficient phagocytosis is important for
the healthy, as well as diseased, brain. In an assay of
microglial phagocytosis of Aβ1-42 peptide, M-CSF-treated
microglia were more phagocytic than vehicle-treated
microglia (Figure 4A and C, compared to 4B and D). We
found a greater proportion of highly phagocytic microglia
amongst M-CSF-treated cells compared to vehicle-treated
cells and the percentage of phagocytic microglia from the
total PU.1-positive microglia population is significantly in-
creased with M-CSF (Figure 4C).
M-CSF induces a change in microglial morphology
The morphology of untreated adult human microglia
in vitro is heterogeneous, with cells having variable pro-
trusions and extensions (Figure 5A). A striking effect of
M-CSF on adult human microglia was a change in their
morphology to elongated, slender, bipolar cells (Figure 5B).
A shift in microglial shape to a ‘rod-like’ morphology is
evident under a light microscope after 48 hours of M-CSF
treatment and is more pronounced at 96 hours. This effect
can be quantified using the Metamorph image analysis
tools Elliptical Form Factor and Shape Factor. These mea-
sures of microglial shape show a significant morphological
difference with M-CSF treatment (Figure 5C and D).
M-CSF decreases HLA expression
To further characterize the phenotype of M-CSF-treated
microglia and elucidate the functional significance of the
M-CSF-induced change in morphology, we looked at the
levels of HLA-DP, DQ, DR expressed by microglia.
Human microglial expression of HLA-DP, DQ DR is in-
ducible and is highly variable between cases (from a
sample of ten cases; four cases had high basal microglial
expression of HLA-DP, DQ, DR, three cases had moder-
ate expression and three cases had no expression). In
the majority (six out of seven) of cases which had basal
microglial HLA-DP, DQ, DR expression, M-CSF treat-
ment was found to decrease the level of expression
(Figure 6A and B). Quantification of microglial HLA-DP,
DQ, DR expression clearly shows a significant reduction
with M-CSF (Figure 6C).
Figure 3 Macrophage colony-stimulating factor (M-CSF) increases the division of adult human microglia. (A and B) Immunocytochemical
images of CD45 microglial cell surface marker (red) and Ki67 cell division marker (green). Adult human microglia undergo limited proliferation in
culture, as demonstrated by a lack of co-expression of Ki67 by CD45-immunoreactive microglia in (A). However, M-CSF treatment increases the
number of dividing microglia, as shown by microglial nuclear expression of Ki67 (B). Arrows indicate examples of Ki67-immunopositive microglia.
(C) Quantification of the percentage of microglia that incorporate BrdU under control conditions and with M-CSF treatment showing a significant
increase in microglial division with M-CSF. P < 0.01, n = 6. Scale bar = 50 μm.
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On the other hand, no change in CD45 expression
was observed with M-CSF treatment (Figure 2). When
the morphological analysis quantification tools were ap-
plied to CD45-immunopositive and HLA-DP, DQ, DR-
immunopositive microglia under basal conditions, there
was no difference in Elliptical Form Factor or Shape
Factor morphology parameters.
M-CSF increases microglial expression of C/EBPβ
transcription factor and DAP12 adaptor protein
To investigate the molecular events precipitated by M-CSF
treatment, we looked for changes in factors known to be
associated with PU.1. From the CCAAT enhancer-binding
protein (C/EBP) transcription factor family, we detected an
increase in C/EBPβ expression within microglia in mixed
glial cultures with M-CSF treatment (Figure 7). A quantifi-
able increase in the percentage of PU.1-immunoreactive
microglia expressing C/EBPβ was found following M-CSF
treatment (Figure 7G). While the percentage of CD45-
positive microglia expressing PU.1 (100%) did not change
with M-CSF treatment, the percentage of CD45-positive
microglia expressing C/EBPβ was increased with M-CSF
treatment. C/EBP-β is known to interact with PU.1 and
may be associated with the increase in PU.1 expression
levels (Figure 2F).
DAP12 is a myeloid adapter protein found in microglia
in the human brain [42]. Signaling through DAP12 has
been associated with the PU.1 transcription factor [22].
Figure 4 Macrophage colony-stimulating factor (M-CSF) increases microglial phagocytosis of amyloid-β1-42. (A) Microglial nuclei labeled with
PU.1 (red) are surrounded by fluorescently labeled amyloid-β1-42 peptide (green) that has been phagocytosed by the microglia. (B) M-CSF treatment
for 96 hours increases the amount of amyloid-β1-42 that has been phagocytosed by microglia. Another demonstration of this is shown in (C) and (D)
where all nuclei are labeled with Hoechst and microglia are labeled with cell surface marker CD45 (red). Arrows indicate highly phagocytic microglia.
(E) M-CSF significantly increases the percentage of microglia that undergo phagocytosis. P < 0.0001, n = 6. Scale bar = 50 μm.
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Figure 5 Macrophage colony-stimulating factor (M-CSF)-treated microglia assume a rod-like shape. (A and B) Immunocytochemical labeling
of CD45 microglial cell surface protein shows the morphology of adult human microglia in vitro. (A) Basal adult human microglial morphology is
heterogeneous - some microglia are more rounded and others are more ramified. (B) A shift in microglial shape to a rod-like morphology is evident
after 48 hours M-CSF treatment. This significant elongation of microglia with M-CSF can be quantified using Metamorph Elliptical Form Factor
(elongation; P < 0.001, n = 16) (C) and Shape Factor (roundness; P < 0.01, n = 16) (D) image analysis tools. Scale bar = 100 μm.
Figure 6 Microglial expression of HLA-DP, DQ, DR is reduced by macrophage colony-stimulating factor (M-CSF). (A) Representative
image of basal HLA expression (green) in cultured adult human microglia. HLA expression is highly variable between cases and is expressed by
some, but not necessarily all, microglia (PU.1-positive nuclei, red). (B) Following 96 hours exposure to M-CSF, the level of microglial HLA
expression was found to be decreased compared to basal levels. (C) Quantification of the effect of M-CSF on HLA expression shows a significant
reduction in the number of microglia expressing HLA. P < 0.0001, n = 18. Scale bar = 100 μm.
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We found that M-CSF increased expression of DAP12
in adult human microglia such that, concurrent with
the increase in PU.1 and C/EBPβ, there is a significant,
quantifiable increase in intensity of DAP12 staining
(Figure 8).
M-CSF increases microglial expression of M-CSF and
IGF-1 receptors
As shown in Figure 1D, adult human microglia express
the M-CSF receptor, CSF-1R, in vitro. Furthermore, on
exposure to M-CSF (25 ng/ml) for 96 hours, microglial
expression of CSF-1R was increased (Figure 9C and G).
We see again an increase in microglial number after ex-
posure to M-CSF but we also see an increase in intensity
of CSF-1R staining (Figure 9I).
We also assessed levels of another mitogenic growth
factor receptor, Insulin-like growth factor 1 receptor (IGF-
1R), which has previously been reported to be linked to
M-CSF signaling [43]. M-CSF treatment co-incidentally
increased microglial expression of both IGF-1 (Figure 9D,
H and J) and M-CSF receptors (Figure 9C, G and I).
Discussion
M-CSF has numerous interesting effects on adult human
microglia, many of which may have significance for a
range of neurological diseases.
The numbers of PU.1 and CD45 immunopositive cells
were increased by M-CSF treatment and we have shown
that this is at least partially through an increase in
microglial division. This division effect was immediately
apparent as adult human microglia do not frequently
divide when cultured in basic medium (DMEM/F12 +
FBS + PSG). This observation is in line with previous
studies noting a proliferation effect with M-CSF for hu-
man fetal microglia [14], and up-regulation of M-CSF
following axotomy of the rat facial nucleus which trig-
gered microglia to proliferate [17]. Many myeloid cells
have been shown to have M-CSF growth dependence
[44]. It may be that adult human microglia require M-
CSF for division, but not for survival, in vitro. The pro-
portion of microglia that undergo division is specific to
each individual patient. However, the result of increased
microglial division with M-CSF treatment is consistent
between cases.
Figure 7 Macrophage colony-stimulating factor (M-CSF) increases adult human microglial expression of C/EBPβ. (A-C) C/EBPβ is
expressed by PU.1-immunopositive adult human microglia in mixed glial cultures. (D-F) M-CSF increases the intensity of C/EBPβ labeling in adult
human microglia and the number of microglia which express C/EBPβ. (G) Quantification of microglial C/EBPβ expression showing that M-CSF
increases the percentage of microglia which express C/EBPβ. P < 0.001, n = 12. Scale bar = 100 μm.
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It has previously been shown that microglia in the rat
brain, as well as the BV2 rodent microglial cell line,
constitutively express a high level of PU.1 in both the
‘normal’ and post-injury state [45]. We have recently
shown that microglia in the adult human brain also ex-
press the transcription factor PU.1 [23]. Previous stud-
ies have demonstrated that PU.1 regulates the M-CSF
receptor [25]. We have found here that PU.1 also acts
down-stream of M-CSF signaling, as PU.1 protein expres-
sion is increased in microglia following M-CSF treatment
(Figure 2). PU.1 has been shown to be involved in M-CSF
-dependent proliferation of mouse bone-marrow macro-
phages [24] and thus it is likely that PU.1 is involved in the
M-CSF-induced proliferation of adult human microglia, as
well as many of the other processes discussed below.
Phagocytosis is an important innate function of micro-
glia as part of their role to respond to cell injury and
regulate the extracellular environment. We found that
M-CSF increased adult human microglial phagocytosis
of Aβ1-42 peptide by microglia from different cases, re-
gardless of the starting level of phagocytosis. In the con-
text of Alzheimer’s disease it is thought that microglia
may be helpful in clearing the brain of extracellular de-
posits of Aβ1-42 protein [46,47]. M-CSF has been shown
to be beneficial in Alzheimer’s disease mouse models
and one mechanism that may be responsible for this ef-
fect is increased phagocytosis of Aβ1-42 [30]. In another
recent study using human microglia, M-CSF treatment
(in combination with IL-4 and IL-13) increased micro-
glial phagocytic ability for myelin debris compared to
microglia stimulated with a combination of GM-CSF,
IFNy and LPS [48].
We have previously found that PU.1 is necessary for
basal phagocytosis in human adult microglia [23]. DAP12
also appears to be involved in the phagocytic process [49]
and associates with proteins which have been found to
play a role in phagocytosis, for example CD68, TREM2
and SIRPB1 [42,50]. Given the M-CSF-induced increases
in PU.1 and DAP12 expression, it is likely that these pro-
teins are involved in M-CSF-dependent phagocytosis in
adult human microglia.
Another prominent effect of M-CSF on adult human
microglia is their change in morphology to bipolar, elon-
gated (‘ramified’) cells. Microglial morphology is presumed
to relate to their function, although exactly how is cur-
rently unclear. Round ‘amoeboid’ microglia are tradition-
ally viewed as activated, inflammatory microglia. The
M-CSF-induced morphology change could be a sign of
microglia being ‘primed’ towards a particular activation
state. However, microglial phenotype is multifaceted and
M-CSF-induced elongation doesn’t prohibit microglia from
changing morphology when exposed to other molecules,
for example Aβ1-42 which induces changes to their cytoskel-
etons necessary for phagocytosis. Even though the M-CSF-
Figure 8 Macrophage colony-stimulating factor (M-CSF) increases adult human microglial expression of DAP12. (A) DAP12 monocyte/
microglial adaptor protein is expressed by human microglia isolated from biopsy tissue. (B) Treatment of microglia with M-CSF increases their
expression of DAP12 as seen by increased intensity of immunochemical staining. (C) Quantification of DAP12 staining intensity shows a
significant increase in DAP12 expression with M-CSF treatment. P < 0.0001, n = 8. Scale bar = 100 μm.
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treated microglia are more rod-shaped and ‘ramified’ than
vehicle-treated microglia, they have an increased propensity
to phagocytose compared to control microglia of heteroge-
neous morphology.
Durafourt et al. (2012) used the same concentration of
M-CSF as part of an ‘alternative’ macrophage/microglia
activation polarizing protocol. Whereas macrophages under
these conditions had more extended processes, no change
was observed for microglia. It may be that the CD45
marker of microglia used here is better for observing
morphological differences, or that their addition of IL-4
and IL-13 reduced the morphology effect seen in micro-
glia [48]. The M-CSF-induced ‘rod’-like effect has also
been noted for human fetal microglia [14].
Elongated rod-shaped microglia have also been reported
in situ in rodent models of neurological injury including
ischemia [51,52]. Graeber (2010) has reported on micro-
glial rod cells observed in human brain tissue associated
with cognitive symptoms and psychopathologies [10].
Rod-shaped, elongated microglia have been reported in the
Huntington’s disease cortex [6] and in subacute sclerosing
panencephalitis, Alzheimer’s disease and Wilson’s disease
brains [53]. In concordance with our findings, Wierzba-
Bobrowicz et al. (2002) also noticed proliferating cell
nuclear antigen co-labeling with rod microglia and re-
duced expression of HLA compared to more rounded
microglia [53].
Rod-shaped microglia are relatively under investigated
[10] and our study presents some of the first functional
results relating to the findings of rod-microglia in human
brain tissue. If M-CSF-treated adult human microglia are
indeed in vitro correlates of the ‘rod’ microglia reported in
diseased adult human brain tissue, this will provide an in-
valuable tool for investigation into this particular micro-
glial phenotype. Furthermore, our method for quantifying
microglial morphology is a quick, high throughput and
unbiased way of assessing these changes, compared to la-
borious and subjective quantification by eye.
To determine the functional relevance of the morph-
ology change and to look further at the activation state of
these M-CSF-exposed microglia, we investigated whether
their expression of HLA was affected. HLA-DP, DQ, DR is
Figure 9 Macrophage colony-stimulating factor (M-CSF) increases adult human microglial expression of CSF-1R and IGF-1R. M-CSF treatment
does not significantly alter the total number of Hoechst-labeled nuclei in human adult mixed glial cultures (A and E), but it does increase the number of
microglia (B and F), as shown by labeling for the microglial transcription factor PU.1. Together with an increase in microglia number, M-CSF produces an
increase in microglial expression of its receptor CSF-1R (C and G) and the receptor for IGF-1 (D and H). A significant increase in intensity of receptor
labeling is found for both CSF-1R (I; P < 0.0001, n = 8) and IGF-1R (J; P < 0.01, n = 8) following M-CSF treatment. Scale bar = 50 μm.
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an inducible protein and we find that its expression by
microglia varies widely between cases. We asked whether
this inducible expression of HLA-DP, DQ, DR was mod-
ulated by M-CSF and found that, despite an increased
number of microglia, fewer microglia express high levels
of HLA-DP, DQ, DR with M-CSF. HLA-DP, DQ, DR
expression by microglia is often taken to represent an
‘activated’ or inflammatory microglial phenotype. Our
results suggest that M-CSF-treated microglia may be
alternatively activated and have reduced antigen pres-
entation capacity.
This M-CSF effect of reduced HLA-DR has also been
noted for human fetal microglia [14]. Furthermore, ex-
pression of HLA class II molecules was noted to be less
intensive on the surface of microglial rod cells compared
to neighboring ramified microglia in neurologically dis-
eased human brain tissue [53]. In the different context of
mouse monocytic precursor cells, Henkel et al., (2002)
found that M-CSF-induced maturation increased MHC
class II expression with IFNy [22]. This finding indicates
that the effect of M-CSF on HLA may be dependent on
cell differentiation stage and/or species. Conversely, Melief
et al. (2012) have recently shown that the ‘alternative’ acti-
vating cytokine IL-4 increases HLA-DR mRNA expression
whilst also inducing an elongated morphology in adult
human microglia [54]. Overall, these results demonstrate
the wide phenotypic diversity of microglia.
An HLA-DQ-derived peptide has been found to have
anti-proliferative effects [55], suggesting that the decrease
in HLA-DP, DQ, DR seen in the present study may be
mechanistically related to the increase in microglial prolif-
eration also seen with M-CSF. Thus decreased HLA may
not only have implications for antigen presentation, but
perhaps for other cellular functions like proliferation.
Of particular interest in our study is that an up-
regulation of PU.1 with M-CSF correlates, in general, with
a less activated microglial phenotype (for example, re-
duced HLA-DP, DQ, DR expression), although phagocyt-
osis was stimulated. This contrasts with a recent report by
Ponomarev et al. showing that increased PU.1 was associ-
ated with an activated microglial phenotype in rodents
[56]. The most likely reason for these different results is
species differences, highlighting the importance of study-
ing adult human brain microglia.
To decipher the mechanisms by which the M-CSF-
induced phenotypic changes occur in microglia, we
looked for changes in factors known to be associated
with the transcription factor PU.1.
CCAAT enhancer-binding protein (C/EBP) transcrip-
tion factors are expressed throughout the body including
the brain [45,57]. The C/EBP family has already been
shown to have a number of species-specific regulation
processes and expression patterns [57]. From the C/EBP
transcription factor family we detected an increase in
C/EBPβ expression within microglia in human mixed
glial cultures treated with M-CSF.
C/EBPβ plays numerous roles in activation and differen-
tiation of macrophages [57]. It has been reported to have
a role in inflammatory processes in rodents [58-60] and
may play a role in differentiated macrophage morph-
ology [61]. Although our studies find increased C/EBPβ
along with increased microglial proliferation, C/EBPβ has
been reported to inhibit proliferation of human THP-1
monocytic cells and murine macrophage-like cells [61].
However, other reports have shown that C/EBPβ can
promote proliferation [57] and furthermore, be involved
in M-CSF-directed mechanisms in tumors [62] and HIV
infection [63]. C/EBP transcription factors including C/
EBPβ can transactivate the CSF-1R promoter in mam-
malian cell line COS-7 cells [64], and could also be in-
volved in the increase in CSF-1R expression observed
in our experiments. C/EBPβ has recently been demon-
strated in human spinal cord tissue from amyotrophic
lateral sclerosis patients, but rarely in controls, co-localized
with the microglial marker CR3 [58].
C/EBPβ forms heterodimers with members of its own
family and interacts with several other transcription fac-
tors [57] including PU.1 [65,66]. M-CSF-mediated enhanced
PU.1 and C/EBPβ transcription factor protein expression
have also been reported for a murine myeloblastic cell line
[67]. Furthermore, co-expression of PU.1 and C/EBPβ in
fibroblasts can induce a macrophage phenotype [44]. PU.1
and C/EBPβ transcription factors together may be respon-
sible for many of the M-CSF induced effects we find in
adult human microglia.
DAP12 is a myeloid adapter protein found in microglia
in the brain. We found that M-CSF treatment of adult
human microglia increased their DAP12 expression. It
has been shown to be involved in M-CSF-induced prolif-
eration and survival of mouse bone marrow-derived mac-
rophages [68]. The concurrent increase in DAP12 protein
expression with increased adult human microglia number
and proliferation suggest a role for DAP12 in this M-CSF-
induced mechanism. DAP12 could also be involved in
the process of phagocytosis as primary mouse microglia
transduced with mutant DAP12 have reduced phagocytic
ability [50].
Henkel et al. (2002) demonstrated an upregulation of
DAP12 in PU.1-rescued monocytic precursor cells and
Weigelt et al. (2007) have shown that DAP12 expression
is dependent on PU.1 via a binding site in the DAP12
proximal promoter [22,49]. Thus the M-CSF-induced in-
crease in DAP12 expression may be directly mediated by
the increase in PU.1. Furthermore, the role of M-CSF in de-
termining PU.1 and DAP12 expression in microglia may
have implications for many neurological diseases [69].
CSF-1R expression is shown here to be restricted to
microglia, and not detected on other cell types in our
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cultures, both basally and with M-CSF treatment. In
addition, we found that M-CSF increased the expression
of its receptor on microglia. The increase in PU.1 found
with M-CSF treatment is likely to directly increase CSF-1R
levels as it has been reported to regulate c-fms transcript
expression [25]. Yamamoto et al. (2010) have also found
that M-CSF increases microglial CSF-1R expression in
the context of the rat axotomized facial nucleus [17].
Coincidentally, M-CSF treatment also increased micro-
glial expression of the IGF-1 receptor. There have been a
number of associations previously reported between the
growth factors M-CSF and IGF-1 [43]. Both factors are
mitogenic, play critical roles in development and have simi-
lar regulation mechanisms. In a study of mouse macro-
phage tumor cells, Wessells et al. (2004) found C/EBPβ to
have a critical role in cell survival, in part by regulating
expression of IGF-I. Furthermore, M-CSF was found to
compensate for IGF-1 and could rescue IGF-1-deficient
cells [70]. The overlapping functions of these ligands
may explain the simultaneous increase in both the CSF-1
and IGF-1 receptors in response to M-CSF.
Another CSF-1R ligand, IL-34, has recently been dis-
covered and is expressed throughout the body, including
the brain [71]. Like M-CSF, IL-34 is involved in human
monocytic proliferation and viability [71,72] but its bio-
logical activity and signal activation are not identical to
that of M-CSF [72]. Furthermore, it has been suggested
that the in vivo role of IL-34 may differ between rodents
and humans [72], and research into the effects of this
cytokine on microglia in the human brain are warranted.
Conclusions
M-CSF dramatically influences the phenotype of adult
human microglia. We have found that M-CSF has many
fascinating effects on these human brain cells and has an
important role in determining microglial phenotype and
function in the context of the adult human brain. How-
ever, the in vivo implications of these results are yet to
be determined. Therapeutically, it would be desirable to
have the ability to modulate microglial phenotype towards
a protective role. To this end, M-CSF-induced human
microglia are worthy of further investigation.
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